US 11879017
Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
granted A61KA61K2039/505A61K2239/31
Quick answer
US patent 11879017 (Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61K2239/31, A61K2239/38, A61K2239/47